Press and media
Press releases
More regular updates and key information, updates and news can be found thorugh our tweets
CellCentric presents early haem clinical data at ASH
CellCentric to present haem clinical data at ASH
CellCentric strengthens leadership team
Latest tweets from @CellCentric
Great to be in Chicago, #ASCO23. Continuing to progress inobrodib, our pioneering oral p300/CBP inhibitor drug. Making a difference to people with cancer.
Our Dir. Clinical Operations, Karen is speaking at the @ECMC_UK meeting on Wed. A great partnership, advancing innovative drugs for people with cancer.
Inobrodib, an easy to take oral drug for the widest R/R multiple myeloma community. Podcast recorded earlier this year: https://www.cellcentric.com/wp-content/uploads/2023/01/Optimumcellcentric-podcast_1_Mix4_AP_No-Intro-and-Outro.mp3
Great to be in Chicago, #ASCO23. Continuing to progress inobrodib, our pioneering oral p300/CBP inhibitor drug. Making a difference to people with cancer.
Our Dir. Clinical Operations, Karen is speaking at the @ECMC_UK meeting on Wed. A great partnership, advancing innovative drugs for people with cancer.
Inobrodib, an easy to take oral drug for the widest R/R multiple myeloma community. Podcast recorded earlier this year: https://www.cellcentric.com/wp-content/uploads/2023/01/Optimumcellcentric-podcast_1_Mix4_AP_No-Intro-and-Outro.mp3
Great to be in Chicago, #ASCO23. Continuing to progress inobrodib, our pioneering oral p300/CBP inhibitor drug. Making a difference to people with cancer.
Our Dir. Clinical Operations, Karen is speaking at the @ECMC_UK meeting on Wed. A great partnership, advancing innovative drugs for people with cancer.
Inobrodib, an easy to take oral drug for the widest R/R multiple myeloma community. Podcast recorded earlier this year: https://www.cellcentric.com/wp-content/uploads/2023/01/Optimumcellcentric-podcast_1_Mix4_AP_No-Intro-and-Outro.mp3